Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration
Related news for (PCSA)
- Closing Bell Spotlight: Momentum Names from Yesterday Continue to Roar
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/08/25 07:00 AM
- Today’s Top Performers: MoBot’s Market Review 10/08/25 06:00 AM
- MoBot alert highlights: NASDAQ: ACXP, NASDAQ: PCSA, NASDAQ: SLRX, NASDAQ: XTLB, NYSE: BURU (10/07/25 06:00 PM)
- Morning Market Snapshot: Small‑Caps and Bio Tools Jockey for Attention